Author pages are created from data sourced from our academic publisher partnerships and public sources.
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Antibodies are important therapeutic agents for cancer. Recently, it has become clear that antibodies possess several clinically relevant mechanisms of action. Many clinically useful antibodies can… Expand
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
The purpose of the National Cancer Institute pilot project to prioritize cancer antigens was to develop a well-vetted, priority-ranked list of cancer vaccine target antigens based on predefined and… Expand
Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
The clinical development of checkpoint inhibitor-based immunotherapy has ushered in an exciting era of anticancer therapy. Durable responses can be seen in patients with melanoma and other… Expand
Monoclonal antibody therapy of cancer
The most significant recent advances in the application of monoclonal antibodies (mAbs) to oncology have been the introduction and approval of bevacizumab (Avastin), an anti–vascular endothelial… Expand
Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors.
Antibody drugs are widely used in cancer therapy, but conditions to maximize tumor penetration and efficacy have yet to be fully elucidated. In this study, we investigated the impact of antibody… Expand
Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site.
- R. Schier, A. McCall, +7 authors J. Marks
- Biology, Medicine
- Journal of molecular biology
- 8 November 1996
We determined the extent to which additional binding energy could be achieved by diversifying the complementarity determining regions (CDRs) located in the center of the antibody combining site of… Expand
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody.
- K. Foon, X. Yang, +12 authors G. Schwab
- International journal of radiation oncology…
- 1 March 2004
The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein, with an extracellular ligand-binding domain and intracellular tyrosine kinase domain. Ligand binding induces EGFR… Expand
High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.
Antitumor monoclonal antibodies must bind to tumor antigens with high affinity to achieve durable tumor retention. This has spurred efforts to generate high affinity antibodies for use in cancer… Expand
Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma Therapy1
- Liat Binyamin, R. Alpaugh, T. L. Hughes, C. Lutz, K. Campbell, L. Weiner
- Biology, Medicine
- The Journal of Immunology
- 1 May 2008
Human NK cells lyse Ab-coated target cells through the process of Ab-dependent cellular cytotoxicity (ADCC). Improving ADCC responses is desirable because it is thought to be an important antitumor… Expand
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.
- H. Kaufman, W. Wang, +7 authors L. Weiner
- Journal of clinical oncology : official journal…
- 1 June 2004
PURPOSE A phase II clinical trial was conducted to evaluate the feasibility and tolerability of a prime/boost vaccine strategy using vaccinia virus and fowlpox virus expressing human… Expand